Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-1132
version: 2
kind: revised
reason: Editorial pass: sharper headline; gain/problem restated as concrete outcomes.
timestamp: 2026-11-04T09:50:25.487861Z
status: published
lens: g_space
sector: health
headline: Development and validation of a machine learning clinicogenomic model to improve prognostic stratification in ER-positive/HER2-negative early breast cancer
dek: Background Several gene expression signatures (GESs) are used for risk stratification in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER-positive/HER2-negative) early breast cancer. Recent integrative approaches combine tumour proliferation, estrogen receptor signalling, immune activity, and clinicopathologic features, yielding gains in prognostic accuracy. We therefore developed a machine-learning-based clinicogenomic prognostic model integrating a research-grade implementation…
gain_title: In three external retrospective datasets, an AI model combining gene scores and clinical features identified low-risk groups 33.8% to 111.8% larger than the standalone 21-gene score while keeping similar or higher survival estimates.
problem_title: (none)
trace_subject: (none)
gain_reading: In three external retrospective datasets, an AI model combining gene scores and clinical features identified low-risk groups 33.8% to 111.8% larger than the standalone 21-gene score while keeping similar or higher survival estimates.
gain_evidence: identified larger low-risk groups than the standalone 21-gene RS | improved discrimination over the standalone 21-gene RS across validation datasets
problem_reading: (none)
problem_evidence: (none)
quick_read: Researchers developed and externally validated a machine-learning-based clinicogenomic model for ER-positive/HER2-negative early breast cancer using four independent datasets totaling 5,132 patients. The random survival forest integrated a research-grade 21-gene recurrence score, a 14-gene immunoglobulin signature, and clinicopathologic features, and was tested against the standalone 21-gene score.

By the September 2026 publication date, retrospective validation showed the model identified 33.8% to 111.8% larger low-risk groups while maintaining survival estimates, and improved discrimination with concordance index gains of 0.035 to 0.058. The work remains retrospective and research-grade, so prospective clinical utility, treatment decision impact, and generalizability beyond the studied datasets remain uncertain.
limitation: Findings are based on retrospective analysis of microarray and RNA-sequencing data using a research-grade implementation of the 21-gene recurrence score, not prospective clinical deployment
tag: Evidence-backed gain
key_points: Retrospective integrative analysis included four independent datasets totaling n = 5132 systemically untreated or endocrine-treated patients | One dataset used for development of random survival forest model, three datasets used for external validation | Model incorporated research-grade implementation of 21-gene recurrence score, 14-gene immunoglobulin signature, and clinicopathologic features | External validation showed relative increases of 33.8 to 111.8% in low-risk group size while maintaining similar or higher horizon-specific survival estimates
rundown: The study developed a random survival forest model using one dataset and validated it in three independent external datasets of systemically untreated or endocrine-treated patients. Performance was compared to a standalone research-grade 21-gene recurrence score using risk stratification, discrimination measured by concordance index and integrated area under time-dependent ROC, and prediction error via Cox-recalibrated integrated Brier score.

Explainability analyses showed time-dependent contributions: the 21-gene RS and clinicopathologic variables drove early prognostic performance while the immune component contributed a smaller but more stable effect over time. Risk separation measured by difference in restricted mean survival time was consistently greater for the RSF model.
sources:
- peer_reviewed | Breast Cancer Research | https://doi.org/10.1186/s13058-026-02388-4 | 2026-09-16
prev: f6733a1526cc7415e032deff75149f113c95553d91ed6c6ebf4f87f400156fd1

sha256

0ce1c069443a836092e555d284f283a6488bbe11c02488a53c34be28f97c3eff

previous

f6733a1526cc7415e032deff75149f113c95553d91ed6c6ebf4f87f400156fd1